Both PCSK9 inhibitors (evolocumab and alirocumab), having received FDA approval in 2015, have been approved for use in people with existing CV disease to reduce the risk of stroke, myocardial infarction, and coronary revascularization [5]. The gene discussed is PCSK9; the disease is stroke disorder.